Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2017-07-13 Capital/Financing Update
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Appendix 3B 9 pages 109.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new securities, including the number of shares issued, terms of the securities, issue price, purpose of the issue, and application for quotation on the ASX (Australian Securities Exchange). The document also includes a quotation agreement and details about employee options issued under an employee share option plan. This type of document is a formal announcement related to capital raising and securities issuance rather than a full financial report or earnings release. It matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not a report itself but a detailed announcement of a new share issue and related securities information.
2017-07-13 English
Change of Director's Interest Notice 2 pages 576.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including shareholdings and contracts related to shares. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions and interests, consistent with insider trading disclosures. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives. The document length and content confirm it is not a brief announcement or a certification but a detailed insider transaction report.
2017-06-26 English
Appendix 3B 9 pages 728.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of additional securities by Mayne Pharma Group Limited. It includes detailed information about the class of securities issued, number of securities, issue price, purpose of the issue, and compliance with ASX listing rules. The document also contains a quotation agreement and details about employee options issued under an employee share option plan. The content is regulatory in nature, focused on the issuance and quotation of new shares, and does not contain financial statements or management discussion. It is not an annual report, earnings release, or management report. The document fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes.
2017-06-26 English
FDA approval and first generic launch of Acticlate tablets 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the FDA approval and immediate commercial launch of a generic pharmaceutical product by Mayne Pharma. It contains no financial statements, no detailed financial analysis, no regulatory certifications, or voting results. It is a corporate announcement about product approval and launch, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being attached or published. The content is a straightforward corporate announcement about a product launch and FDA approval, which is best classified as a general Regulatory Filing (RNS) because it does not fit any other specific category.
2017-06-14 English
Appendix 3B 9 pages 108.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new shares, including the number of securities issued, terms, issue price, purpose, and compliance with ASX rules. It also includes a quotation agreement and details about employee options issued under an employee share option plan. The document is regulatory in nature, focused on the announcement and application for quotation of new securities rather than a financial report or earnings release. This matches the description of a Share Issue/Capital Change announcement. Therefore, the appropriate classification is SHA (Share Issue/Capital Change). The document length and detail support a high confidence score.
2017-06-08 English
2016 Sustainability Report 42 pages 9.3MB
Environmental & Social Information Classification · 100% confidence The document is titled 'Sustainability Report 2016' and explicitly states it is the first Sustainability Report published by Mayne Pharma Group Limited. It follows the Global Reporting Initiative (GRI) Standards and covers economic, environmental, and social impacts of the company's operations. The content includes sections on governance, compliance, risk management, environmental data, social responsibility, and economic contributions. There is no indication that this is an annual financial report, audit report, or earnings release. Instead, it focuses on environmental, social, and governance (ESG) factors, which aligns with the definition of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is Environmental & Social Information (SR).
2017-06-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.